Inogen, Inc (INGN)

From the record

Inogen, Inc's filings since 2017 show no warning events in the scan: no bankruptcy or receivership notice, no debt default notice, no exchange listing notice, no restatement warning, no auditor change, no material cyber incident and no late-report notice (its current reports).

From the record

Inogen, Inc's 10 filed years say what it did: revenue went from $203 million in fiscal 2016 to $349 million in fiscal 2025, up 6.2% a year; it rose in 7 of 9 years; the deepest fall was 16% from fiscal 2022 to fiscal 2023; net income was positive in 4 of 10 of those years (its annual reports).

From the record

Return on equity: in the fiscal year ended 2025-12-31, Inogen, Inc lost about 12 cents for every dollar of shareholders' money, and gross profitability: its products earned about 52 cents per dollar of everything the company owns. Leverage: it owed about 36 cents per dollar of assets, and net share issuance: its share count grew 12.5% over the year (the filed statements).

From the record

Inogen, Inc's standing among 26 graded names in its industry family: revenue of $349 million in fiscal 2025 ranks in the top 40% by size; a net margin of -6.5% ranks in the top 44%; revenue growth of -2.6% a year over the last 3 filed years ranks in the bottom 17% (its annual reports).

From the record

Inogen, Inc's leadership, from its insiders' filings and its current reports: the chief executive on the record is Smith, Kevin Raymond Merrill (CEO and President, as filed), filing under that title since 2023-11-13, 3 years (bottom 44% of its family); the 15 officers and directors filing in the last fifteen months have been on the record a median of 2.7 years (bottom 9%); 17 officer or director changes were reported on Form 8-K since 2023-11-13, against the 15 people in charge now (bottom 16%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

Inogen, Inc's room to grow, from the newest filed statements (fiscal 2025): cash of $104 million against no long-term debt tagged leaves 34.7% of its assets as net cash, top 24% of its family; cash from operations less capital spending is -3.9% of revenue (top 46%); a gross margin of 44.2% (bottom 42%); research spending of 5.6% of revenue (bottom 33%) (its annual report).

From the record

Inogen, Inc's growth drivers, from the filed years to fiscal 2025: revenue grew -2.6% a year over the last three filed years against 6.2% over all 10, slowing (bottom 22% of its family); the newest year grew 3.9% (bottom 42%); research spending grew -4% a year (bottom 31%); capital spending grew -8.9% a year (bottom 27%) (its annual reports). Inogen, Inc tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.

From the record

Inogen, Inc's newest year against its own record: revenue of $349 million in fiscal 2025 came in 10.1% above the $317 million its prior three years' pace pointed to (top 15% of its family); net income of $23 million against a prior three-year average of $74 million (top 11%); a net margin of -6.5% against -21.8% before (top 15%) (its annual reports).